<DOC>
	<DOCNO>NCT02767128</DOCNO>
	<brief_summary>The main purpose determine pharmacokinetics ( PK ) Triferic iron administer orally healthy adult volunteer . It randomize multiple treatment , single dose study .</brief_summary>
	<brief_title>Pharmacokinetics Absolute Bioavailability Fer-In-Sol Triferic Administered Orally With Shohl 's Solution Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1/2 , randomize multiple treatment , single dose study assess pharmacokinetics ( PK ) absolute bioavailability Fer-In-Sol ( Ferrous Sulfate ) Triferic ( ferric pyrophosphate citrate , FPC ) administer orally Shohl 's solution healthy volunteer . Total participation study approximately six week comprise screen visit , 6 treatment period , follow-up visit . The study conduct 13 day period : Day 1 use determine baseline serum iron profile subject . Each subject subsequently receive randomize sequence Day 2 10 : 1 . A single oral dose Fer-In-Sol 3 mg Fe/kg body weight ( bw ) . 2 . A single oral dose Oracit Shohl 's solution 0.67 mEq/L ( 0.7 ml/kg bw ) follow 10 minute Fer-In-Sol 3 mg Fe/kg bw 3. single oral dose Triferic PO 3 mg Fe/kg bw 4. single oral dose Oracit Shohl 's solution 0.67 mEq/L ( 0.7 ml/kg bw ) administer 10 minute prior single oral dose Triferic 3 mg Fe/kg bw . 5. single oral dose Oracit Shohl 's solution 0.67 mEq/L ( 0.7 ml/kg bw ) follow immediately single oral dose Triferic 3 mg Fe/kg bw . All subject receive single dose 6.6 mg Triferic 4 hour IV infusion ( mimic 4 hour iron tolerance test ) Day 12 . Blood sample obtain various time analyze serum iron parameter safety .</detailed_description>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . The patient must able provide inform consent personally sign date study write informed consent document complete studyrelated procedure . 2 . The patient hemoglobin , MCV reticulocyte value within reference range gender . ( Male : Hgb ≥13.0 g/dL ; Female Hgb ≥ 12.0 g/dL ) Screening . 3 . The patient must transferrin saturation ( TSAT ) ≥20 % Screening . 4 . The patient must total iron binding capacity ( TIBC ) ≥250 ug/dL Screening . 5 . The patient must serum ferritin within follow reference range gender Screening : ( Males : 23336 ng/mL ; Females : 11306 ng/mL ) . 6 . The patient must agree discontinue iron preparation 14 day prior Baseline . 7 . If patient female , must nonpregnant nonlactating , least 90 day postpartum ( applicable ) Screening . Women childbearing potential must willing use appropriate birth control entire duration study . 8 . The patient must willing able comply study procedure restriction . 9 . The patient must clinically significant abnormal finding medical history , vital sign , physical examination , clinical laboratory result Screening . 10 . The patient must body mass index ( BMI ) ≤35.0 kg/m2 Screening . 1 . The patient administration oral iron supplement within 14 day prior Baseline . 2 . The patient receive IV iron within 6 month prior Screening . 3 . The patient serum CRP concentration upper limit normal Screening Baseline ( &gt; 6.0 mg/L ) . 4 . The patient concurrent recurrent disease ( e.g. , cardiovascular , renal , hepatic , gastrointestinal , malignant , etc . ) could affect action disposition investigational product utilized study , could affect clinical laboratory assessment . 5 . The patient acute illness within 14 day prior Baseline . 6 . The patient currently use medication ( include prescription , overthecounter ( OTC ) , herbal , homeopathic preparation ) within 14 day prior Baseline . Exceptions contraceptive , hormone replacement therapy , acetaminophen , nonsteroidal antiinflammatory drug . 7 . The patient know suspected intolerance hypersensitivity ironcontaining product . 8 . The patient history alcohol substance abuse within past year . 9 . The patient positive screen cotinine drug abuse . 10 . The patient positive HIV , hepatitis B , hepatitis C history . 11 . The patient donate blood blood product ( e.g. , plasma platelet ) within 30 day prior Screening . 12 . The patient participate investigational drug study within 30 day prior Screening . 13 . The patient pregnant intend become pregnant completing study . 14 . The patient 's current medical status , investigator 's opinion , would preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy adult volunteer</keyword>
</DOC>